On behalf of International Society for Cutaneous Lymphomas (ISCL), it is our pleasure to invite you to the 6th World Congress of Cutaneous Lymphomas (6WCCL) which will be held from June 25 to 27, 2026, in Montréal, Canada – a city renowned for its vibrant culture and historic significance.

Building on the tremendous success of the 5th WCCL, hosted by City of Hope in Pasadena, California—with over 400 delegates in attendance—we are confident that the upcoming 5WCCL will once again deliver a program of exceptional scientific and clinical value. Ensure to submit your abstracts to help shape the scientific program, with opportunities for both oral and poster presentations. Participants will benefit from cutting-edge presentations on the latest research findings, clinical innovations, and emerging multidisciplinary approaches to patient care.

Traditionally every 4 years, we are excited to transition the WCCL to be held every 2 years. This significant initiative of the ISCL reflects the growing global reach of the congress, drawing participants from the North and South Americas, Europe, Middle East, Australia and Asia. The multidisciplinary nature of our members includes dermatologists, haemato-oncologists, radiation oncologists, pathologists and dermatopathologists, scientists, dermatology nurses, psychologists, pharmacologists, and many others – ensuring a rich and comprehensive forum for in-depth discussions covering all aspects of cutaneous lymphomas.

The meeting will include competitively scored scientific abstracts, discussions for a revised staging of MF/SS and blood classification for MF/SS, the latest clinical studies, genome-wide studies on genetic alterations in different clinical entities, the clinical implications of these molecular events on the pathogenesis of cutaneous lymphomas and their potential role as future therapy targets. Interactive sessions, workshops, and debates will feature through the program and an educational program will also be available.

The ISCL was brought to life in 1992 by a small group of cutaneous lymphoma enthusiasts who founded ISCL in a little café in downtown New York City. The ISCL founders had a dream of organizing an umbrella organization to facilitate sharing of information to coordinate scientific activities worldwide. Since 1992, annual ISCL meetings were held across the globe bringing alive the dreams of our founders. ISCL-led efforts have improved communication and understanding of the pathological processes in cutaneous lymphomas and developed a staging system in 2007 and global response assessment 2011 – and updated in 2022 – to allow better assessment of our patients response to therapies and in clinical trials. Continued efforts to understand the disease course and responses to therapies have been possible from the PROCLIPI Study, an international prospective prognostic index study, opened in 2015. PROCLIPI has just published a CLIPI (A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification.Blood.2025.Blood.2025029628.doi: 10.1182/blood.2025029628) to stratify patients with advanced MF/SS into risk groups for overall survival at diagnosis to allow better management decisions and improve survival.

The ISCL reflects the spirit of collaboration we are working toward on all levels, for the shared goal of developing a better understanding and management of cutaneous lymphomas in the relentless search of a cure. We are grateful to all for making the 6th WCCL a success and are delighted to welcome you in Montreal.

Join us in advancing knowledge and improving outcomes for patients worldwide.

We eagerly anticipate your participation in Montréal.